. Author manuscript; available in PMC: 2015 Jun 29.

Published in final edited form as: Lipids. 2011 Jun 2;46(10):907–921. doi: 10.1007/s11745-011-3572-y

Table 1.

Summary of 3dSB-IBP inhibitor interactions in MTT cytotoxicity assays

Combination	Cell line
	RPMI-8226	U266	SF-295	A549
	3dSB + Lov	Synergistic^a	Synergistic^a	Synergistic^a	Synergistic^a
	3dSB + ZA	Additive^b	Antagonistic^d	Antagonistic/Additive^f	ND
3dSB + DGBP	Antagonistic^c	Antagonistic^d	Additive^b	ND
3dSB + Zara	Antagonistic^e	Antagonistic^e	ND	ND

Cells were incubated in standard FCS for 48 h in the presence of 3dSB and/or IBP inhibitors (Lov lovastatin, ZA zoledronic acid, DGBP digeranyl bisphosphonate, Zara zaragozic acid) prior to the addition of MTT salt. Combination indices (CI) for ED₃₀ and ED₅₀ (unless otherwise specified) were determined via isobologram analysis

ND Not determined

CI < 0.8 as determined by isobologram analysis

CI 0.8–1.2 as determined by isobologram analysis

CI > 1.2 as determined by isobologram analysis

MTT Activity of combination > 3dSB alone as determined by two-tailed t testing

CI’s for ED₂₀ and ED₃₀ calculated

CI antagonistic for ED₃₀ and additive for ED₅₀